

PRECISION EVENTS CALENDAR

Next-Gen Commercialization Services | September 2023

UPCOMING CONFERENCES AND EVENTS



■ September 11-14 Digital Pharma East

Precision Value & Health experts will be at booth 31. Stop by to learn more about actionable omnichannel benchmarking research and meet the team.



■ September 20 Endpoints 11 Awards

Anshul Mangal, Precision ADVANCE President, will be presenting at the Endpoints 11 Awards Ceremony, hosted by Endpoints News. This awards gala honors the 11 most promising biopharma startups in 2023.



■ October 10-12 Meeting on the Mesa

Precision ADVANCE will be hosting multiple events throughout this meeting from their sponsored cocktail hour to the featured preliminary session "A Deep Dive into the Future of Advanced Therapies". Make sure you don't miss out on our experts!

ON-DEMAND WEBINARS & WHITE PAPERS

■ Endpoints Webinar – The Future of Cell Therapy Development and Delivery (ICYMI)

Featuring: John Khoury, Chris McDonald, Phil Cyr, Andy Kinley

Explore the latest strategies through this on-demand webinar for navigating the complexities of cell therapy development and identify clinical development best practices for a successful execution.

■ Consequences of the IRA on Oncology Care Providers

Featuring: Jeff Becker

Increase your understanding of how the Inflation Reduction Act impacts your customers and gain insights from experts representing both provider and policy perspectives.

■ White Paper: Cell and Gene Therapies: How High Can Prices Go?

Featuring: Richard Macaulay, David Carr


Launch prices for gene therapies have climbed steadily higher, with recent therapies more than triple the launch price of the first gene therapies approved in 2012. Read this insightful white paper that deliberates what is reasonable when it comes to breakthrough science and unprecedented therapeutic solutions.

THOUGHT LEADERSHIP

■ The Role of the Pharma Industry in Superseding Outdated Medical Practices

By: Ross Maclean, Philip Cyr and Ray Roth

When should older, now outdated technologies, be phased out in favor of newer, better alternatives? Precision experts discuss the reluctance to abandon practices and technologies despite the availability of newer, better alternatives, and list how biopharma can lead the way.



■ What's Behind the Slow Uptake of Biosimilars in the US?

By: Dan Danielson

Why would a payer prefer a more expensive reference brand? Learn more about findings from a new analysis that explains why many plans aren't yet sold on giving less expensive biosimilars better footing on formularies compared to reference products.



ACCELERATE YOUR SUCCESS. Schedule time today with one of our experts by emailing info@precisionvh.com. Visit us at www.precisionvh.com and follow us on [LinkedIn](#).